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Abstract
Background: The development of new therapeutic strategies to treat amyotrophic lateral sclerosis (ALS) is of
utmost importance. The use of cyclic nitroxides such as tempol may provide neuroprotection and improve lifespan.
We investigated whether tempol (50 mg/kg) presents therapeutic potential in SOD1G93A transgenic mice.
Methods: Tempol treatment began at the asymptomatic phase of the disease (10th week) and was administered
every other day until week 14, after which it was administered twice a week until the final stage of the disease. The
animals were sacrificed at week 14 (initial stage of symptoms—ISS) and at the end stage (ES) of the disease. The
lumbar spinal cord of the animals was dissected and processed for use in the following techniques: Nissl staining to
evaluate neuronal survival; immunohistochemistry to evaluate astrogliosis and microgliosis (ISS and ES); qRT-PCR to
evaluate the expression of neurotrophic factors and pro-inflammatory cytokines (ISS); and transmission electron
microscopy to evaluate the alpha-motoneurons (ES). Behavioral analyses considering the survival of animals,
bodyweight loss, and Rotarod motor performance test started on week 10 and were performed every 3 days until
the end-stage of the disease.
Results: The results revealed that treatment with tempol promoted greater neuronal survival (23%) at ISS compared
to untreated animals, which was maintained until ES. The intense reactivity of astrocytes and microglia observed in
vehicle animals was reduced in the lumbar spinal cords of the animals treated with tempol. In addition, the groups
treated with tempol showed reduced expression of proinflammatory cytokines (IL1β and TNFα) and a three-fold
decrease in the expression of TGFβ1 at ISS compared with the group treated with vehicle.
Conclusions: Altogether, our results indicate that treatment with tempol has beneficial effects, delaying the onset
of the disease by enhancing neuronal survival and decreasing glial cell reactivity during ALS progression in
SOD1G93A mice.
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Background
Amyotrophic lateral sclerosis, with a global prevalence
of 4–8 cases per 100,000 individuals, is the fourth lead-
ing cause of death by neurodegenerative diseases and
follows Parkinson’s, Alzheimer’s, and Huntington’s dis-
ease. The ALS is characterized by selective and progres-
sive degeneration of both upper and lower motoneurons
[1–3]. The degenerative process is followed by intense
muscular atrophy and sequential paralysis and death,
usually by respiratory failure. The clinical signs emerge
when neuronal degeneration reaches a critical point be-
yond compensatory mechanisms, generating denervation
and muscular weakness. Initially, such partial degener-
ation is compensated for by the surviving neurons,
which, through axonal sprouting, increase the size of the
motor units. However, this mechanism eventually fails,
and the cell bodies of the motoneurons become visibly
abnormal and completely degenerate [4]. The disease
progression is fast, with 50% of patients dying due to re-
spiratory complications within 2 to 5 years after the
onset of symptoms [5].
The discovery of SOD1 mutations led to the develop-
ment of transgenic mouse models and provided a mech-
anism to investigate the disease pathogeneses. These
animals present several aspects of the clinical profile ob-
served in human patients with the disease, representing
an excellent model for the study of pathological mecha-
nisms of ALS [6].. Although the specific mechanism
responsible for inducing ALS has not yet been eluci-
dated, the pathophysiology of the disease appears to be
multifactorial, including glutamate excitotoxicity, oxida-
tive stress, mitochondrial dysfunction, altered protein
control, and neuroinflammation, which are pivotal fea-
tures in both ALS in humans and in ALS mouse models
[7–9]. Of note is the active role of non-neuronal cells,
such as astrocytes, microglial, and T lymphocytes, which
characterize ALS as a non-cell autonomous disease [10].
In physiological conditions, astrocytes and microglia play
important functions in the maintenance and protection
of the central nervous system (CNS). They participate in
several mechanisms, such as providing trophic factors,
regulating glutamate concentration and controlling syn-
aptic function [11]. Importantly, it has been shown that
astrocytes and microglia are capable of modifying the
disease progression of SOD1 transgenic mice [12, 13].
Despite evidence regarding several disease mechanisms,
the ALS etiology remains unknown.
Although ALS has been described for more than a
century, until last year, riluzole was the only drug ap-
proved by the FDA for ALS treatment. More recently,
the FDA approved an antioxidant edaravone for the
treatment of the disease, and both drugs present a mod-
est increase in the survival of patients. Therefore, the
discovery of new therapeutic strategies and drugs that
can act in different pathways to promote a better quality
of life for patients is urgently needed. The class of cyclic
nitroxides has become a possible candidate for the treat-
ment of neurologic disorders in the central and periph-
eral nervous system. These drugs are multifunctional
antioxidants and present low toxicity in vitro and in vivo
[14–16]. Tempol (4-hydroxy-TEMPO) is considered a
cyclic nitroxide with low molecular weight and excellent
cellular permeability. Although tempol is mainly charac-
terized as an antioxidant, several studies demonstrated
other effects in different pathological conditions of the
nervous system, including anti-apoptotic, anti-
inflammatory, immunomodulatory, and therapeutic pro-
prieties [17–23]. It is also established that tempol re-
stores muscular force in normal and dystrophic animals
[24, 25], demonstrating that tempol can be considered a
candidate for the treatment of neurodegenerative dis-
eases. In this way, the aim of the present study was to
investigate the neuroprotective effects of tempol for the
treatment of ALS in a transgenic mouse model.
Methods
Ethics statements
All animal procedures were conducted according to the
guidelines of the Brazilian College for Animal Experi-
mentation. Experiments and animal handling were ap-
proved by the Institutional Committee for Ethics in
Animal Experimentation (Committee for Ethics in Ani-
mal Use, Institute of Biology, CEUA/IB/UNICAMP),
protocols n° 3304–1 and 4501–1/2017.
Mice
The strain used was B6SJLTg (SOD1G93A), which was
developed by Gurney et al. 1994, and it carries a mutant
allele of human SOD1 containing the Gly 93 ➔ Ala sub-
stitution. The breeding pairs were originally obtained
from the ALS Foundation through Dr. R. Brown (Uni-
versity of Massachusetts) and subsequently donated by
Dra. Rosália Mendez-Otero (Instituto de Biofísica Carlos
Chagas Filho, UFRJ). The colony was maintained by
crossing transgenic males with wild-type female mice.
The genotyping of animals and the number of human
SOD1 transgenic copies was assessed as described in the
Jackson Laboratory manual (Tables 1 and 2). These ani-
mals are characterized by presenting disease onset at
Table 1 Primer sequences used for the genotyping of all
animals
Primers Sequence
Human SOD forward 5′ CAT CAG CCC TAA TCC ATC TGA 3′
Human SOD reverse 3′ TCT TAG AAA CCG CGA CTA ACA ATC 5′
Mouse SOD forward 5′ GCA ATC CCA ATC ACT CCA CAG 3′
Mouse SOD reverse 3′ GTC CAT GAG AAA CAA GAT GAC 5′
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approximately 90 days and survival at 130 days (Fig. 1).
For this study, female and male mice were used in equiva-
lent numbers.
Drugs and treatments
The treatment with 50mg/kg tempol (Sigma-Aldrich 176,
141) or 8mg/kg riluzole (Sun Pharmaceutical Ind. Ltd.,
India) started on the 10th week of life and was performed
orally (gavage). The animals of the vehicle group received
water alone instead of drug treatment. Between the 10th
and 14th weeks, the animals were treated every other day.
After this time point, the treatment continued twice a week
until the end-stage of the disease. The doses employed in
this study were based on previous studies [23, 26].
Disease progression assessments
The progression of the disease was evaluated in all trans-
genic mice twice a week from the 10th week of age until
end-stage by a researcher blinded to the treatment. The
parameters measured included body weight, latency to
fall in the Rotarod test, and neurological score.
Survival of transgenic mice
The survival of the animals was considered to be the age
at which the animals were unable to return to the quad-
ruple position within 30 s after being placed in dorsal
decubitus.
Evolution of disease
Bodyweight measurements were used to determine dis-
ease onset and the symptomatic stage. All mice were
weighed twice a week beginning on the 10th week until
the endpoint. Disease onset was established as the max-
imum weight recorded for each animal retrospectively.
The symptomatic stage was considered when the ani-
mals presented a loss of 10% of their maximum weight
[27]. The difference between the age of onset and the
age of euthanasia was used as a measurement of disease
progression. The neurological score of 0 to 4 was evalu-
ated as described in the strain manual of Jackson Labora-
tory: Working with ALS Mice Guidelines for preclinical
testing & colony management from the Jackson Laboratory
(http://jackson.jax.org/rs/444-BUH-304/images/Working_
with_ALS_Mice.pdf).
Fig. 1 Experimental design, treatments, and methods employed to test the efficacy of tempol on the early symptomatic stage of ALS in the
transgenic SOD1G93A mouse model
Table 2 Primer sequences used to assess the copy number of
human SOD1 in transgenic mice
Primers Sequence
IMR1544 CAC GTG GGC TCC AGC ATT
IMR3580 TCA CCA GTC ATT TCT GCC TTT G
IMR9655 GGG AAG CTG TTG TCC CAA G
IMR9666 CAA GGG GAG GTA AAA GAG AGC
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Motor performance
Rotarod (EFF 412, Insight, Brazil) tests were conducted
twice a week from the 10th week of age until the end
stage, while possible. The mice had up to 8 min to remain
in the rotating bar at a constant speed of 5 rpm. The time
until the mice dropped from the cylinder was recorded.
Tissue preparation for histological examination
Following the predetermined periods of treatment,
namely, 14 weeks (onset of symptoms) and the end-stage
of the disease (Table 3), the animals were anesthetized
with Kensol (xylazine, König, Argentina, 10 mg/kg) and
Vetaset (ketamine, Fort Dodge, USA, 50 mg/kg) and
were subjected to transcardial perfusion with 0.1M
phosphate buffer saline (PBS), followed by fixative (para-
formaldehyde 4% in 0.1M phosphate buffer—PB; pH 7,
4). The lumbar spinal cords were removed, postfixed in
the same fixative solution for 12 h at 4 °C, washed with
phosphate buffer (PB), and sequentially cryopreserved in
10%, 20%, and 30% PB-sucrose (12 h in each concentra-
tion). The samples were individually frozen in n-hexane,
which was cooled in liquid nitrogen at − 35 °C. Trans-
verse sections (12 μm thick) of lumbar spinal cords were
obtained with a cryostat and transferred to gelatin-
coated slides, dried at room temperature for 30 min, and
stored at − 20 °C until utilization. After reaching room
temperature, the sections were then stained with cresyl
violet to count the motoneurons and subjected to
immunolabeling.
Nissl staining and motoneuron counting
The motoneurons were localized based on morphology and
ventral horn location. The total number of motoneurons in
the ventral horn of the lumbar spinal cord was counted in
alternate sections of each specimen in approximately 20
sections. The interval between sections was 48 μm. Only
cells with a visible nucleus and nucleolus were counted. To
correct for the double-counting of motoneurons, because
the same cell may be present in two sections, we used the
Abercrombie’s formula [28] as follows:
N ¼ nt= t þ dð Þ
N is the corrected number of counted neurons, n is
the counted number of cells, t is the thickness of the
sections (12 μm), and d is the average diameter of the
cells. Due to the possibility of differences in cell size
among experimental conditions, the value of d was cal-
culated specifically for each experimental group. Thus,
the diameter of 30 randomly chosen neurons present at
the ventral horn lamina IX of each group was measured
and the mean diameter obtained was applied to the for-
mula (approximately 40 μm).
Immunofluorescence
Immunofluorescence was evaluated in three representa-
tive alternate sections of the lumbar spinal cord (12 μm
thick). After blocking with 150 μL 3% BSA (bovine
serum albumin) in 0.1 M PB for 45 min, the slides were
incubated with rabbit anti-GFAP (Abcam 1:1500-
AB7779) and rabbit anti-Iba1 (Wako, 1:700–01919741),
diluted in an incubation solution containing 1.5% BSA
and 0.2% Tween in 0.1M PB and incubated for 4 h at
room temperature. After washing with 0.01M PB, the
secondary antibodies (CY-3, anti-mouse, or anti-rabbit,
Jackson Immunoresearch; 1:250) were applied and incu-
bated for 45 min. The sections were then rinsed in 0.01
M PB and mounted in a mixture of glycerol/PB (3:1).
For quantification measurements, 3 representative
images of the ventral horn of the lumbar spinal cord
were captured from each animal for all experimental
groups using a Leica fluorescence microscope (DM
5500, Wetzlar, Germany) equipped with a coupled
digital camera (DFC 345 FX, Wetzlar, Germany) using
the specific filters according to the secondary antibodies.
A quantitative evaluation of labeling was carried out
using the integrated density of pixel measurements in a
fixed area corresponding to the ventral horn, as
described by [29]. Quantification was performed with
ImageJ software (version 1.33u, National Institutes of
Health, USA). The integrated pixel density was calcu-
lated for each section, and the mean values for each
experimental animal were computed. The data are pre-
sented as the mean ± standard error of the mean (SEM)
for each group.
Transmission electron microscopy
For ultrastructural analysis, the animals were killed at the
end-stage of the disease with a lethal dose of halothane
(Tanohalo, Cristália Chemicals, and Pharmaceuticals,
Table 3 Experimental groups and distribution of animal numbers for each technique




n° RT-qPCR (14th) n° TEM
(end-stage)
NTG (non-transgenic) 6 6 5 3
Vehicle 6 6 5 3
Riluzole 6 6 5 3
Tempol 6 6 5 3
Chiarotto et al. Journal of Neuroinflammation          (2019) 16:218 Page 4 of 14
Itapira-SP, Brazil), and the vascular system was transcar-
dially perfused in a similar manner to that described in
the “Tissue peparation for histological examination” sec-
tion. After saline perfusion, the animals were fixed with a
solution containing 2.5% glutaraldehyde and 0.5% parafor-
maldehyde in phosphate buffer 0.1M (pH 7.4). The lum-
bar spinal cord was removed and stored overnight in the
same fixative solution at 4 °C. The samples were trimmed
and osmicated, dehydrated in ethanol and acetone, and
embedded in Durcupan ACM (Fluka, Steinheim,
Switzerland). The blocks were trimmed, and semithin sec-
tions (0.5 μm) were obtained and stained with 0.25% tolui-
dine blue for light microscopy observation. Ultrathin
sections (70 nm), from the right and left sides of the ven-
tral horn, were made in an ultramicrotome (Leica Ultracut
UCT Ultramicrotome), collected on formvar-coated
single-slot grids, contrasted with uranyl acetate and lead
citrate, and examined under a Tecnai G2 Spirit BioTwin
(FEI, The Netherlands) transmission electron microscope
operating at 80 kV.
Analysis of the ultrathin sections
Neurons with large cell bodies (> 35 μm in diameter) lo-
cated in the ventral horn of the spinal cord were identi-
fied as α-motoneurons by the presence of C-type nerve
terminals. The surface of these cells was then sequen-
tially digitized at a magnification of 13,000× using a
video camera (Eagle, FEI, Eindhoven, The Netherlands)
connected to a computerized system. The images were
then mounted together in vector graphics software
(Adobe Photoshop CS4 Extended, Adobe Systems Incor-
porated, San Jose, CA, USA). A total of two motoneurons
were evaluated per animal of each experimental group.
Both the motoneurons and the neuropile were evaluated
with respect to the degeneration process of the disease.
RT-qPCR
The lumbar spinal cord was dissected and immediately fro-
zen in liquid nitrogen and stored at − 80 °C. Total RNA was
extracted using a specific RNeasy Lipid Tissue Mini Kit
(Qiagen-cat n° 74,804), and reverse transcription was syn-
thesized with 2.0 μg total RNA with the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems–4,
368,814) according to the manufacturer’s instructions. Fol-
lowing cDNA synthesis, real-time PCR was performed using
a TaqMan Assay (Life Technologies) to evaluate the relative
gene expression levels of neurotrophic factors (BDNF and
GDNF), anti-inflammatory cytokines (TGFβ1 and IL10) and
pro-inflammatory cytokines (TNFα, IL1β, IFNγ, and iNOS)
(Table 4). For the PCR template, cDNA specimens in tripli-
cate were used with the TaqMan Gene Expression Master
Mix (2×) (Life Technologies–PN 4369016) and TaqMan as-
says (primers + hydrolysis probes) for the genes listed in
Table 4 in a volume of 20 μL, employing 45 cycles for
amplification at 95 °C for 10min, followed by 95 °C for 15 s
and 60 °C for 1min. The reference gene was carefully se-
lected based on unchanged expression under several experi-
mental conditions. The HPRT1 reference gene was labeled
with a VIC fluorophore and the target genes were labeled
with a FAM fluorophore. The entire procedure for the
quantitative PCR was performed on the instrumentation
platform MX3005P (Agilent, Santa Clara, CA, USA), and
the results were calculated with MxPro software (Agilent).
For statistical analysis, the mean values of the three mea-
surements for each animal were used as individual data for
the relative quantification of the genes of interest using the
2−ΔΔCt method [30].
Statistical analysis
For the survival analysis, Kaplan-Meier curves and log-
rank tests (Mantel-Cox) were employed. For quantitative
data analysis of neuronal survival, immunohistochemis-
try, and RT-qPCR, one-way ANOVA were used,
followed by intergroup difference post hoc evaluation
with Tukey’s test (parametric data). The Rotarod and
body weight evaluations were analyzed using two-way
ANOVA and the post hoc Bonferroni’s test. The level of
statistical significance was 95% (p < 0.05).
Results
Tempol delays the bodyweight loss and the motor deficit
in the Rotarod test associated with ALS progression
The behavioral analyses (body weight and Rotarod test)
were performed with experimenters blinded to treatment
groups twice a week, starting at 10 weeks of age until 17
weeks (advanced symptomatic stage). The data obtained
from the behavioral tests revealed an earlier loss of body
weight (12 weeks) in the SOD1G93A mice treated with
riluzole and vehicle compared to the NTG group, start-
ing from the asymptomatic phase of the disease (Fig. 2a).
The group treated with tempol showed alterations
1 week later (13 weeks). This delayed weight loss was
present in the tempol-treated group until the advanced
stages of disease (17 weeks) and was significantly











Chiarotto et al. Journal of Neuroinflammation          (2019) 16:218 Page 5 of 14
different from the riluzole-treated group (p < 0.001). In
addition, the results obtained from the Rotarod test
demonstrated improved motor performance in the ani-
mals treated with riluzole and tempol compared with
that in the vehicle group (Fig. 2b). The behavioral im-
provement observed correlated positively on the survival
of the animals, as shown in Fig. 2c. Thus, the group
treated with tempol showed a trend towards increased
lifespan compared with the other groups.
Tempol attenuates neuronal loss during ALS progression
in SOD1G93A transgenic mice
Spinal MNs count was performed in the lumbar spinal
cord, particularly in the segments related to the sciatic
nerve. This region is characteristically afflicted by the
disease in SOD1G93A ALS mice. Thus, large lumbar
MNs within the ventral horn lamina IX were counted by
using Nissl staining at each time point. The percent
change in the number of motoneurons in the transgenic
SOD1G93A mice and in the non-transgenic mice was cal-
culated, which represents the ratio of neuronal survival
during ALS progression.
Despite all the drastic alterations that result from the ALS
degeneration process observed with TEM (Additional file 1:
Fig. S1), the tempol treatment showed promising results. At
14 weeks, SOD1G93A mice showed a reduction of MNs of
approximately 58% (vehicle), 53% (riluzole), and 36% (tem-
pol) with respect to non-transgenic (NTG) littermates. The
neuroprotection observed with tempol treatment was main-
tained until the end-stage of the disease, with 64% neuronal
survival. These results were correlated with the improved ul-
trastructural preservation of the ventral horn of the spinal
cord the tempol group compared to the ultrastructure of
the vehicle and riluzole groups. The following percent
changes in the number of motoneurons for each group were
observed at 14weeks: NTG (99%± 7.1%, mean ± standard
error); vehicle (46% ± 2.3%); riluzole (51%± 2.0%); and tem-
pol (69%± 1.6%). The following percent changes for each
group were observed at end-stage: NTG (100%± 4.8%); ve-
hicle (41.7% ± 2.1%); riluzole (46.8% ± 2.7%) and tempol
(64.8% ± 0.5%) (Fig. 3). The total number of counted moto-
neurons is also provided (Additional file 2: Table S1). Im-
portantly, within each group, male and female presented
similar numbers of MNs (Additional file 3: Fig. S2).
Tempol immunomodulates glial cell reactions during ALS
progression
It has been suggested that glial cells act as the protagon-
ist of neuroinflammation during motor neurodegenera-
tion in ALS. Therefore, we evaluated glial cell activation
in the lumbar spinal cord during ALS progression (14
weeks and end-stage of disease). As expected, the
Fig. 2 Behavioral analysis and survival. Tempol treatment delayed body weigt loss (a) and improved motor performance in the Rotarod test (b)
compared to SOD1G93A mice treated with vehicle or riluzole. Each point in the graphs represents the mean ± SEM. Data were analyzed by two-
way ANOVA for repeated measures, followed by a post hoc Bonferroni test. Treatment with tempol showed no significant change in survival (c)
compared to SOD1G93A mice treated with vehicle. The results were evaluated with the log-rank test p = 0.5088. *** vs NTG, ### vs vehicle (p <
0.0001); && vs riluzole (p < 0.001)
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immunohistochemical detection of GFAP showed strong
astrogliosis in the spinal cord of SOD1G93A mice com-
pared with that of non-transgenic littermates (p <
0.0001). The analysis showed lower astrocyte activation
(GFAP+) in tempol-treated mice than in vehicle-treated
(134%) and riluzole-treated (83%) mice at the early
symptomatic stage (14 weeks). The activation of astro-
cytes progressed until the end-stage of the disease. The
following percent changes in GFAP quantification for
each group were observed at 14 weeks: NTG (99.3% ±
10.8%, mean ± standard error); vehicle (281.5% ± 16.5%);
riluzole (230.3% ± 11.3%); tempol (147.3% ± 8.2%); end-
stage: NTG (99.5% ± 11.01%, mean ± standard error);
vehicle (387.7% ± 9.5%); riluzole (401.5% ± 11.04%); tem-
pol (337.8% ± 8.8%) (Fig. 4). Of note, within each group,
male and female presented comparable astroglial reac-
tion (Additional file 3: Fig. S2).
Similar data were obtained with respect to microglial
activation (Iba1+). Tempol treatment decreased micro-
glial reactivity by 83% in the ventral horn of the spinal
Fig. 3 Histological sections of the lumbar spinal cord of non-transgenic and SOD1G93A transgenic mice stained with cresyl violet (a, b, d, e, g, h,
j, k) and semithin sections of the ventral horn of the spinal cord stained with toluidine blue (c, f, i, l). Scale bar: 50 μm. m Neuronal survival
percentage, 14 weeks and end stage of ALS. Data were analyzed by one-way ANOVA, followed by post hoc Tukey’s test. ***p < 0.0001 vs NTG;
##p < 0.001 and ###p < 0.0001 vs vehicle; &&p < 0.001 and &&&p < 0.0001 vs riluzole
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Fig. 4 (See legend on next page.)
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cord at 14 weeks compared with the vehicle treatment.
In the end-stage of ALS, the reduction in microgliosis
was maintained by tempol (107%) in the ventral horn of
the spinal cord. This effect was also observed in the
intermediate region with a reduction of 104% compared
with the vehicle group and 46% compared with the rilu-
zole group. Additionally, in the dorsal region, 48% and
30% less reactivity was observed in the tempol group
compared with the reactivity in the vehicle and riluzole
groups, respectively.
The following percent changes in Iba1 quantification
for each group were observed at 14 weeks: NTG
(100% ± 7.3%, mean ± standard error); vehicle (347.8% ±
16.2%); riluzole (292.8% ± 11.1%); and tempol (264.2% ±
13.68%). The following percent changes were observed
at the end-stage: NTG (99.8% ± 9.3%), vehicle (444.4% ±
10.4%), riluzole (384.2% ± 9.5%), and tempol (337% ±
9.5%) in the ventral horn; NTG 99% ± 2.3%), vehicle
(376.2% ± 9.7%), riluzole (318.7% ± 9.3%), and tempol
(272.5% ± 4.8%) in the intermediate region; and NTG
(102% ± 4.8%), vehicle (185.7% ± 3.2%), riluzole (177.7% ±
2.4%), and tempol 147.8% ± 3.2%) in the dorsal horn
(Fig. 5). Importantly, within each group, male and female
presented similar degree of microglial reactivity (Add-
itional file 3: Fig. S2).
Tempol decreases the activation of neurotrophic factors
in the early symptomatic stage of ALS
The gene expression of the neurotrophic factors BDNF
and GDNF was assessed at 14 weeks by RT-qPCR. The
BDNF gene expression increased in the vehicle group
compared with the non-transgenic mice (p < 0.0001).
However, riluzole and tempol treatments showed similar
reduction in the BDNF expression when compared with
vehicle group (p < 0.05 and p < 0.001). (NTG (0.97 ±
0.04), vehicle (1.4 ± 0.05), riluzole (1.1 ± 0.08), tempol
(1.07 ± 0.07)) (Fig. 6a).
GDNF gene expression also increased in the transgenic
mice groups compared with that of NTG; however, tem-
pol treatment showed a reduction when compared with
the vehicle group p < 0.05. NTG (1.01 ± 0.05), vehicle
(2.81 ± 0.27), riluzole (1.94 ± 0.03), tempol (1.92 ± 0.16)
(Fig. 6b).
Tempol downregulates the gene expression of inflammatory
cytokines in the early symptomatic stage of ALS
In addition, the expression of pro- and anti-inflammatory
cytokines was evaluated at 14 weeks. The IL1β transcript
levels increased in transgenic mice: vehicle, riluzole, and
tempol treatment by 14-, 10-, and 6-fold, respectively,
compared to NTG mice. Tempol treatment promoted a
9-fold reduction compared with vehicle treatment p <
0.0001 and 6-fold reduction compared with riluzole treat-
ment p < 0.05. NTG (0.96 ± 0.08), vehicle (15.5 ± 1.32),
riluzole (11.97 ± 3.5), tempol (6.08 ± 0.65 (Fig. 7a).
Similar results were observed in TNFα gene expres-
sion, with higher levels in transgenic mice: vehicle, rilu-
zole, and tempol treatment resulted in a 15-, 11-, and 6-
fold increase, respectively, compared to NTG mice.
Tempol again reduced the levels of TNFα by 9.5-fold
when compared with vehicle (p < 0.0001; NTG (1.2 ±
0.14), vehicle (16.4 ± 1.7), riluzole (12.3 ± 3.1), and tem-
pol (6.9 ± 0.61) (Fig. 7b).
The IFNγ transcript levels increase in vehicle group in
respect NTG littermates (p < 0.001); however, no statis-
tical differences were observed among the experimental
groups NTG (1.0 ± 0.11), vehicle (1.8 ± 0.16), riluzole
(1.71 ± 0.41), and tempol (1.49 ± 0.18) (Fig. 7c).
The gene expression of iNOS increased in the vehicle
(p < 0.001) and riluzole (p < 0.001) groups compared to
that of NTG mice. In contrast, the tempol group main-
tained iNOS levels close to the NTG group and reduced
the iNOS levels in respect to riluzole group (p < 0.05).
NTG (0.99 ± 0.08), vehicle (2.2 ± 0.20), riluzole (2.8 ±
0.69), and tempol (1.78 ± 0.17) (Fig. 7d).
TGFβ1 gene expression increased in the vehicle (p <
0.0001) and riluzole (p < 0.001) groups compared to that
of NTG mice. In addition, tempol treatment reduced the
levels of TGFβ1 by 3-fold with respect to vehicle group.
NTG (1.0 ± 0.03), vehicle (5.4 ± 0.52), riluzole (4.5 ± 1.1),
and tempol (2.4 ± 0.37), (Fig. 7e).
The IL10 transcript levels were similar among all ex-
perimental groups (NTG (1.04 ± 0.09), vehicle (1.1 ±
0.14), riluzole (1.2 ± 0.24), tempol (0.99 ± 0.14)) (Fig. 7f).
Discussion
Amyotrophic lateral sclerosis (ALS) is one of the most de-
bilitating neurodegenerative diseases. Riluzole and edara-
vone are the only options to delay the course of the
disease; however, they offer limited benefits to patients.
Therefore, there is an urgent need to find new therapies
to cure or at least delay the progression of the disease.
The present study showed that oral administration of the
antioxidant tempol, starting in the asymptomatic phase of
ALS, delays motor dysfunction, and exerts immunomodu-
latory effects in SOD1G93A mice, the most established
(See figure on previous page.)
Fig. 4 Images of astrocyte activation in the anterior horn of the spinal cord. The immunolabeling of GFAP was quantified in the early
symptomatic phase (week 14) (a, c, e, g) and at the end stage (b, d, f, h). Scale bar: 50 μm. Graphical representation of percent GFAP expression
at 14 weeks (i) and end-stage (j) of ALS. Data were analyzed by one-way ANOVA, followed by post hoc Bonferroni test. ***p < 0.0001 vs NTG;
###p < 0.0001 vs vehicle; &&p < 0.001 vs riluzole
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mouse model for studying ALS. The improvement in be-
havioral tests was associated with neuroprotective effects
in the spinal cord, which was correlated with increased
motoneuron survival.
Neuroinflammation is the most evident pathological hall-
mark of ALS. Nevertheless, several studies suggest that this
mechanism is not only a late consequence of motoneuron
injury but may have a dual function, contributing to neuro-
protection or leading to neurotoxicity. Initially, glial cells
participate in the protective events aimed at supporting
motoneuron survival. However, after disease onset, astro-
cytes and microglia acquire an aberrant phenotype,
accelerating ALS progression and exacerbating neuronal
degeneration. The threshold that determines the shift be-
tween protection and toxicity is unknown, although it is
clear that the modulation of glial reactivity is a key strategy
to avoid loss of motoneurons during the course of ALS.
Our study showed the efficiency of tempol treatment to
decrease astrogliosis and microglial reactions in the lumbar
spinal cord. It is possible that the antioxidant actions of
tempol reduced oxidative stress, positively influencing the
inflammatory process during the installation of disease.
Our results showed the activation of glial reactivity be-
ginning at the onset of ALS symptoms. At the same time
Fig. 5 Images show microglial activation in the anterior horn of the spinal cord. The immunolabeling of Iba1 was quantified in the early
symptomatic phase (week 14) and at the end stage (a–p). Scale bar: 50 μm. Graphical representation of percent Iba 1 expression at 14 weeks (m)
and end-stage (n, ventral horn), (o, intermediate region), (p, dorsal horn) of ALS. Data were analyzed by one-way ANOVA, followed by post hoc
Bonferroni test. ***p < 0.0001 vs NTG; #p < 0.05, ##p < 0.001, and ###p < 0.0001 vs vehicle; &p < 0.05, &&p < 0.001, and &&&p < 0.0001 vs riluzole
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Fig. 6 Relative expression of the neurotrophic factors BDNF (a) and GDNF (b). Data were analyzed by one-way ANOVA, followed by post hoc
Tukey’s test. *p < 0.05 and ***p < 0.0001 vs NTG; #p < 0.05 and ##p < 0.001 vs vehicle
Fig. 7 Relative expression of inflammatory cytokine s IL1β (a) and TNFα (b), IFNγ (c), iNOS (d), TGFβ1 (e), and IL10 (f). Data were analyzed by one-
way ANOVA, followed by post hoc Tukey’s test. ***p < 0.0001, **p < 0.001, and *p < 0.05 vs NTG; ###p < 0.0001 and #p < 0.05 vs vehicle; &p < 0.05
vs. riluzole
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point (14 weeks), the upregulation of the neurotrophic
factors BDNF and GDNF indicated an effort to rescue
diseased motoneurons. Tempol-treated transgenic mice
displayed fewer neurotrophic factor gene transcripts, in-
dicating reduced degenerative conditions in that group.
Elevated levels of neurotrophic factors were observed in
the lumbar spinal cord and limb muscles of ALS mice
beginning at the asymptomatic stage and increasing pro-
gressively until the end stage of the disease [31, 32]. The
same result was found in tissues of human ALS patients
[33], suggesting the activation of a neuroprotective path-
way through neurotrophic factor expression. Nonethe-
less, such a neuroprotective mechanism is not sufficient
to avoid neuronal degeneration.
As expected, we found elevated levels of TNFα and
IL1β pro-inflammatory cytokines produced by toxic
microglia. These data are in accordance with the en-
hancement of glial reactivity in the initial symptomatic
stage. Thus, astrocytes and microglia, under pathological
conditions or in neurodegenerative diseases, release pro-
inflammatory molecules, activating a signaling cascade
that results in further damage of the CNS. Importantly,
our present data suggest that tempol treatment after
ALS onset can break the degenerative cycle of uncon-
trolled inflammation, inducing a predominantly protect-
ive astrocyte and microglia phenotype in the lumbar
spinal cord of ALS mice.
Our results regarding TGFβ1 expression were in line
with the literature regarding ALS progression [34] dem-
onstrated that the astrocytes of ALS patients and mice
express TGFβ1, increasing the inflammatory response,
which in turn accelerates disease progression. Addition-
ally, the overproduction of TGFβ1 results in decreased
expression of insulin growth factor-I (IGF-I) by micro-
glia and in a reduction of infiltrating T cells. Although
we did not evaluate the expression of TGFβ1 in astro-
cytes alone, our data suggest that the immunomodula-
tory role of tempol reduces astrogliosis as well as the
levels of pro-inflammatory cytokines.
Altogether, our results emphasize that neuroinflamma-
tion has both beneficial and detrimental roles in neurode-
generative diseases. The challenge is to enhance the
protective phase of neuroinflammation and to minimize
its toxic effects. We have previously reported neuroprotec-
tive and anti-apoptotic effects of tempol after a neonatal
lesion in the peripheral nervous system. Accordingly,
other studies reported several positive effects of tempol
in vitro and in vivo in different pathological conditions of
the nervous system. The observed properties include in-
hibition of apoptotic events, anti-inflammatory effects, re-
duced glutamate release in pathologic conditions [18],
modulation of BDNF, reduction of oxidative stress, and
improvement of cognitive capacity in a model of Alzhei-
mer’s disease [20]. In addition, therapeutic effects were
reported in the EAE [19] and neuroprotection was re-
ported in an in vitro model of Parkinson’s disease [21].
The present study shows that tempol is effective in re-
ducing neuronal loss in ALS, even at the end-stage.
Thus, we showed immunomodulatory effects on astro-
cytes and microglia, mostly in the initial symptomatic
stage. Our results are in line with the gene expression
analysis, which showed the downregulation of the pro-
inflammatory cytokines IL1β and TNFα.
It is important to emphasize that the behavioral tests
showed that tempol treatment delayed the motor deficit
by 1 week compared to the vehicle-treated group. How-
ever, despite all the positive effects described, tempol
treatment did not show a statistically significant effect
on the overall survival of ALS mice. Contrasting results
were reported by Linares et al. [35], who showed that
treatment with tempol (26 mg/kg, i.p.), increased the
lifespan of female SOD1G93A mice. In our study, how-
ever, male and female mice were used in similar propor-
tions to compose the different experimental groups.
This may have obscured eventual gender-related effects
[36]. However, in line with our findings, treatment with
sodium valproate, another promising drug, although
providing neuroprotection in SOD1G86R mice did not
extend lifespan. The authors suggested that such result
was related with skeletal muscle denervation [37]. Thus,
due to protocol, strain, and gender variations, conflicting
results make challenging to determine the exact role of
new drug candidates to treat ALS, difficulting the transla-
tion to the clinic. Nevertheless, the present data reinforce
the therapeutic potential of multifactorial antioxidants,
such as tempol, for the treatment of this particular moto-
neuron disease. Further studies are necessary to unveil the
molecular basis of tempol, as well as eventual side effects
of its chronic use.
Conclusion
Overall, our study demonstrates that tempol can be con-
sidered a promising drug to treat ALS due to the im-
proved immunomodulatory and anti-inflammatory effects
compared to riluzole. Tempol showed neuroprotective,
anti-inflammatory, and immunomodulatory properties
throughout ALS progression, reducing body weight loss
and improving motor performance in SOD1G93A mice.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12974-019-1598-x.
Additional file 1: Figure S1. Ultrastructural analysis of the ventral horn
of the lumbar spinal cord at the end stage of ALS in transgenic
SOD1G93A. (A) Cholinergic presynaptic terminal (Type C), necessary for
identification of alpha motoneurons (18,500x). (B) Remaining spinal
motoneuron (890x). (C) Atrophic motoneuron (890x). (D) Phagocytic
microglia observed in the proximity of the neuronal body (2900x). (E)
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Protoplasmic astrocytes observed in the vicinity of the neuronal
membrane. Projections of these cells were observed filling the space
between the presynaptic terminals and the postsynaptic membrane
(2900x). (F) Swollen mitochondria, showing the retraction of crests and
rupture of internal membranes, which are characteristic of mitochondrial
dysfunction (11.000x).
Additional file 2: Table S1. Number of motoneurons counted per
spinal cord section (with Abercrombie’s correction, mean ± standard
error, n = 6 per group).
Additional file 3: Figure S2. Evaluation of neuronal survival, astrocytosis
and migroglial reaction in male and female mice from NTG, vehicle,
riluzole-treated, and tempol-treated groups (14 weeks and end-stage). No
gender differences were observed within each group/treatment (mean ±
standard error).
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